Corbus Pharmaceuticals Holdings IncNASDAQ:CRBP
- LAST PRICE36.5300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots35.0700/ 1
- Ask / Lots37.1100/ 2
- Open / Previous Close0.0000 / 36.5300
- Day Range---
- 52 Week Range
- Volume22
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRBP |
|---|---|---|
| 09:32 ET | 4079 | 37.78 |
| 09:34 ET | 100 | 36.365 |
| 09:36 ET | 1600 | 37.21 |
| 09:38 ET | 1026 | 37.21 |
| 09:39 ET | 153 | 37.62 |
| 09:45 ET | 100 | 37.235 |
| 09:48 ET | 100 | 37.41 |
| 09:52 ET | 100 | 36.855 |
| 09:57 ET | 100 | 37.065 |
| 10:03 ET | 300 | 36.66 |
| 10:06 ET | 400 | 36.57 |
| 10:08 ET | 700 | 36.74 |
| 10:19 ET | 153 | 37.3098 |
| 10:21 ET | 765 | 37.23 |
| 10:26 ET | 150 | 36.9964 |
| 10:28 ET | 100 | 37.08 |
| 10:30 ET | 1109 | 36.98 |
| 10:32 ET | 100 | 36.955 |
| 10:33 ET | 500 | 37.15 |
| 10:35 ET | 550 | 37.14 |
| 10:37 ET | 900 | 37.15 |
| 10:39 ET | 205 | 37.13 |
| 10:42 ET | 100 | 37 |
| 10:48 ET | 100 | 37.03 |
| 11:06 ET | 700 | 37.43 |
| 11:08 ET | 899 | 37.4 |
| 11:09 ET | 400 | 37.53 |
| 11:11 ET | 200 | 37.4801 |
| 11:15 ET | 500 | 37.5201 |
| 11:20 ET | 100 | 37.66 |
| 11:22 ET | 600 | 37.56 |
| 11:27 ET | 305 | 37.45 |
| 11:29 ET | 825 | 37.25 |
| 11:31 ET | 200 | 37.31 |
| 11:38 ET | 129 | 37.2535 |
| 11:42 ET | 400 | 37.01 |
| 11:49 ET | 100 | 36.59 |
| 12:12 ET | 600 | 36.785 |
| 12:16 ET | 312 | 36.68 |
| 12:18 ET | 100 | 36.68 |
| 12:21 ET | 100 | 36.715 |
| 12:23 ET | 736 | 36.84 |
| 12:27 ET | 517 | 36.56 |
| 12:32 ET | 900 | 36.45 |
| 12:34 ET | 100 | 36.44 |
| 12:36 ET | 607 | 36.51 |
| 12:39 ET | 136 | 36.44 |
| 12:45 ET | 1936 | 36.31 |
| 12:48 ET | 200 | 36.35 |
| 12:50 ET | 200 | 36.43 |
| 12:56 ET | 100 | 36.5069 |
| 12:59 ET | 602 | 36.31 |
| 01:01 ET | 250 | 36.415 |
| 01:03 ET | 300 | 36.4 |
| 01:12 ET | 100 | 36.47 |
| 01:21 ET | 900 | 36.36 |
| 01:24 ET | 1100 | 36.305 |
| 01:26 ET | 1100 | 36.305 |
| 01:30 ET | 1200 | 36.34 |
| 01:33 ET | 300 | 36.36 |
| 01:39 ET | 500 | 36.365 |
| 01:44 ET | 500 | 36.42 |
| 01:46 ET | 236 | 36.43 |
| 01:50 ET | 500 | 36.35 |
| 01:53 ET | 600 | 36.375 |
| 01:55 ET | 500 | 36.37 |
| 01:57 ET | 1857 | 36.4 |
| 02:02 ET | 200 | 36.43 |
| 02:08 ET | 200 | 36.4 |
| 02:09 ET | 100 | 36.38 |
| 02:11 ET | 1300 | 36.315 |
| 02:15 ET | 320 | 36.2775 |
| 02:20 ET | 1612 | 36.38 |
| 02:29 ET | 900 | 36.4 |
| 02:31 ET | 100 | 36.415 |
| 02:33 ET | 414 | 36.4 |
| 02:44 ET | 100 | 36.19 |
| 02:49 ET | 1400 | 36.18 |
| 02:51 ET | 2450 | 35.9 |
| 02:54 ET | 100 | 35.76 |
| 02:58 ET | 200 | 35.515 |
| 03:00 ET | 200 | 35.65 |
| 03:02 ET | 550 | 35.6425 |
| 03:03 ET | 1400 | 35.37 |
| 03:09 ET | 500 | 35.26 |
| 03:12 ET | 200 | 35.34 |
| 03:14 ET | 100 | 35.19 |
| 03:18 ET | 300 | 35.39 |
| 03:27 ET | 2400 | 35.62 |
| 03:30 ET | 870 | 35.6 |
| 03:34 ET | 100 | 35.65 |
| 03:36 ET | 1000 | 35.77 |
| 03:38 ET | 1100 | 35.94 |
| 03:39 ET | 500 | 36.06 |
| 03:41 ET | 1360 | 36.16 |
| 03:43 ET | 1100 | 35.91 |
| 03:45 ET | 1800 | 35.97 |
| 03:48 ET | 500 | 35.95 |
| 03:50 ET | 1833 | 36.325 |
| 03:52 ET | 3569 | 36.43 |
| 03:54 ET | 892 | 36.475 |
| 03:56 ET | 2370 | 36.565 |
| 03:57 ET | 800 | 36.5 |
| 03:59 ET | 3173 | 36.53 |
Apr 2, 2024
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC, from 8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 383.8M | -3.5x | --- |
PepGen Inc | 383.2M | -3.6x | --- |
Adlai Nortye Ltd | 393.0M | -6.3x | --- |
Lexeo Therapeutics Inc | 397.7M | -4.5x | --- |
Annexon Inc | 399.7M | -2.5x | --- |
Biomea Fusion Inc | 400.5M | -3.2x | --- |
Company Information
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Contact Information
- Headquarters
- 500 River Ridge DriveNORWOOD, MA, United States 02062
- Phone
- 617-963-0103
- Fax
- ---
Executives
- Independent Chairman of the Board
- Alan Holmer
- Chief Executive Officer, Director
- Yuval Cohen
- Chief Financial Officer
- Sean Moran
- Chief Medical Officer
- Dominic Smethurst
- Independent Director
- Anne Altmeyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $383.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-10.38 |
Book Value | $-1.56 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
